At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 42 enrolled
Drug / intervention
Certolizumab pegol +1 morebiological
Likely dose
Certolizumab pegol 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis
In Brief
A Phase 3 clinical trial evaluating Certolizumab pegol and Placebo for Cystitis, Interstitial. Completed, enrolled 42 participants across 1 site.
Detailed Summary
A Randomized, Double-blind, Placebo Controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystitis, Interstitial
CountriesUnited States
CollaboratorsUCB Pharma
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartDec 2015
Primary CompletionApr 2017
Study CompletionJul 2017
TodayJul 2026
First PostedJul 15, 2015
Enrollment StartDec 15, 2015
Primary CompletionApr 16, 2017
Study CompletionJul 12, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.0 years ago
Interventions
Certolizumab pegolbiological
400 mg
Placebodrug
Normal saline